The purpose of this study is to confirm whether DFL24498 eye drop solution is effective in reducing eye itching and improving other signs of the condition in adults with Atopic Keratoconjunctivitis after six weeks of treatment. The study will measure how much the itching improves, as well as changes in damage to the clear front part of the eye, which is called the cornea, and redness of the white part of the eye, which is called the conjunctiva. The main goal is to see if the investigational eye drops can help relieve the uncomfortable symptoms that people with this condition experience.

During the study, participants will be randomly assigned to receive either DFL24498 eye drops or placebo eye drops, and neither the participants nor the doctors will know which treatment is being given. The treatment will continue for twelve weeks, with regular visits to check how well the eyes are responding and to monitor for any side effects. At these visits, doctors will examine the eyes, ask about symptoms, and assess the overall condition using various measurement scales. The study will track changes in itching levels, the health of the eye surface, and the degree of redness to determine whether the investigational treatment is working better than placebo.

The purpose of the study is to determine if at least one of the doses of Isocyclosporin A is better than the placebo in reducing eye itching. Participants in the study will use the eye drops for four weeks, and their symptoms will be monitored during this time. After the treatment period, there will be a follow-up period of two weeks to continue observing the effects of the medication. The study aims to provide valuable information on how well Isocyclosporin A works for people with AKC and whether it is safe to use.

Throughout the study, participants will be asked to report any changes in their symptoms, such as itching, tearing, and discomfort, as well as any side effects they may experience. The study will also assess the overall quality of life for participants, as well as any changes in their vision. By the end of the study, researchers hope to gather enough data to understand the potential benefits and risks of using Isocyclosporin A for treating Atopic Keratoconjunctivitis.

The purpose of the study is to assess how effective Ikervis is when used four times a day for four months. Participants will be randomly assigned to receive either Ikervis or a placebo. The study will involve regular check-ups to monitor the condition of the eyes and any changes in symptoms. The main focus will be on changes in eye redness, but other aspects like eye comfort and tear production will also be evaluated.

Participants will be asked to use the eye drops daily and attend scheduled appointments for assessments. The study aims to provide valuable information on whether Ikervis can be a beneficial treatment for those suffering from Atopic Keratoconjunctivitis, potentially offering relief from the symptoms associated with this eye condition.